Back HIV/AIDS

HIV / AIDS

Happy Holidays from HIVandHepatitis.com

alt

HIV Infection Linked to Structural Heart Disease

People with HIV who have detectable viral load are more likely to have structural heart problems such as left ventricular hypertrophy, diastolic dysfunction, or pulmonary hypertension, according to research presented at the recent EuroEcho-Imaging 2013 conference in Istanbul.

alt

HIV+ People on ART May Match General Population Life Expectancy

Young adults with HIV in high-income countries who take effective antiretroviral therapy (ART) may live nearly as long as HIV negative people in the general population, according to findings from the NA-ACCORD collaboration published in the December 18, 2013, edition of PLoS ONE.

alt

HIV Triggers CD4 T-Cell Death via Inflammation

HIV infection sets off a vicious cycle of inflammation and cell death dubbed "pyroptosis" -- or fiery cell suicide -- according to a pair of recent reports from researchers at UCSF's Gladstone Institutes.

alt

FDA Approves Complera as Switch Option for People with Suppressed HIV

The U.S. Food and Drug Administration this month expanded the indication for the single-tablet regimen Complera (rilpivirine/tenofovir/emtricitabine, known as Eviplera in Europe). The 3-in-1 combination pill is now approved for people with suppressed viral load who wish to switch regimens.

alt

PrEP Does Not Promote Increased Sexual Risk Behavior among Gay Men

Using Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) to prevent HIV infection was not associated with an increase in sex without condoms and it appears to promote active engagement in risk reduction, according to a report in the December 18, 2013, edition of PLoS ONE.

alt

FDA Approves Complera as Switch Option for People with Suppressed HIV

TEXT

alt